7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Atrial Remodeling D064752 1 associated lipids
Vascular Calcification D061205 1 associated lipids
Angina, Stable D060050 2 associated lipids
Bisphosphonate-Associated Osteonecrosis of the Jaw D059266 1 associated lipids
Osteoporotic Fractures D058866 1 associated lipids
Peripheral Arterial Disease D058729 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Peri-Implantitis D057873 1 associated lipids
Primary Myelofibrosis D055728 6 associated lipids
Chronic Periodontitis D055113 1 associated lipids
Osteophyte D054850 2 associated lipids
Hyperphosphatemia D054559 1 associated lipids
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative D054438 1 associated lipids
No-Reflow Phenomenon D054318 2 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypercalciuria D053565 4 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Fractures, Bone D050723 4 associated lipids
Arteriolosclerosis D050379 1 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Hashimoto Disease D050031 1 associated lipids
Hyperparathyroidism, Primary D049950 1 associated lipids
Diabetes Complications D048909 4 associated lipids
Hypertension, Pregnancy-Induced D046110 2 associated lipids
Scleroderma, Limited D045745 1 associated lipids
Glucose Metabolism Disorders D044882 3 associated lipids
Malnutrition D044342 6 associated lipids
Irritable Bowel Syndrome D043183 8 associated lipids
Mastocytoma D034801 3 associated lipids
Hearing Loss D034381 3 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Spondylarthropathies D025242 1 associated lipids
Spondylarthritis D025241 1 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Carcinoma, Pancreatic Ductal D021441 6 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Multiple Sclerosis, Chronic Progressive D020528 3 associated lipids
Brain Infarction D020520 17 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Lithiasis D020347 2 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Tooth Ankylosis D020254 1 associated lipids
Venous Thrombosis D020246 11 associated lipids
Intracranial Hemorrhage, Traumatic D020198 1 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hot Flashes D019584 5 associated lipids
Bone Marrow Neoplasms D019046 2 associated lipids
Myositis, Inclusion Body D018979 3 associated lipids
Sepsis D018805 11 associated lipids
Arthralgia D018771 8 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Breast Neoplasms, Male D018567 1 associated lipids
Bone Demineralization, Pathologic D018488 1 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Cholesteatoma, Middle Ear D018424 2 associated lipids
Foot Injuries D018409 1 associated lipids
Alphavirus Infections D018354 1 associated lipids
Hemangioma, Capillary D018324 1 associated lipids
Neoplasms, Squamous Cell D018307 1 associated lipids
Carcinoma, Neuroendocrine D018278 2 associated lipids
Carcinoma, Medullary D018276 2 associated lipids
Carcinoma, Lobular D018275 4 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Adrenocortical Adenoma D018246 1 associated lipids
Fibroma, Ossifying D018214 1 associated lipids
Giant Cell Tumor of Bone D018212 1 associated lipids
Lymphangioleiomyomatosis D018192 1 associated lipids
Bone Cysts, Aneurysmal D017824 2 associated lipids
Diabetic Foot D017719 1 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Microvascular Angina D017566 2 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Myocardial Ischemia D017202 11 associated lipids
beta-Thalassemia D017086 5 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Carotid Stenosis D016893 15 associated lipids
POEMS Syndrome D016878 1 associated lipids
Pasteurellaceae Infections D016871 2 associated lipids
Bacteroidaceae Infections D016866 2 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Diabetes, Gestational D016640 8 associated lipids
Severe Combined Immunodeficiency D016511 1 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Fractures, Stress D015775 2 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
HIV Infections D015658 20 associated lipids
Histiocytosis, Non-Langerhans-Cell D015616 4 associated lipids
Hyperostosis D015576 1 associated lipids
Arthritis, Psoriatic D015535 3 associated lipids
Leukemia, Lymphocytic, Chronic, B-Cell D015451 25 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Bénard J [From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin? 2000 Bull Cancer pmid:11184451
Yamashita T et al. Retardation in bone resorption after bone marrow ablation in klotho mutant mice. 2000 Endocrinology pmid:10614667
Hofbauer LC et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. 2000 J. Bone Miner. Res. pmid:10646108
Kanzawa M et al. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. 2000 Eur. J. Endocrinol. pmid:10822231
Atkins GJ et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. 2000 J. Bone Miner. Res. pmid:10780856
Thompson SW and Tonge D Bone cancer gain without the pain. 2000 Nat. Med. pmid:10802700
Honore P et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. 2000 Nat. Med. pmid:10802707
Onyia JE et al. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. 2000 J. Bone Miner. Res. pmid:10804015
Bateman TA et al. Osteoprotegerin mitigates tail suspension-induced osteopenia. 2000 Bone pmid:10773583
Malyankar UM et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. 2000 J. Biol. Chem. pmid:10811631
Thirunavukkarasu K et al. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. 2000 J. Biol. Chem. pmid:10833509
Aubin JE and Bonnelye E Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. 2000 Medscape Womens Health pmid:10792853
Fata JE et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. 2000 Cell pmid:11051546
Miyamoto N et al. Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. 2000 J. Orthop. Res. pmid:11052502
Kinpara K et al. Osteoclast differentiation factor in human osteosarcoma cell line. 2000 J Immunoassay pmid:11071251
Kong YY et al. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. 2000 Immunol. Today pmid:11071528
Kobayashi Y et al. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. 2000 J. Bone Miner. Res. pmid:11028444
Kaneda T et al. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. 2000 J. Immunol. pmid:11035059
Miyamoto T et al. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. 2000 Blood pmid:11110710
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. 2000 Bone pmid:11113385
Takayanagi H et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. 2000 Nature pmid:11117749
Mancini L et al. Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. 2000 Biochem. Biophys. Res. Commun. pmid:11118297
Lee ZH et al. Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. 2000 Mol. Pharmacol. pmid:11093794
Kong YY and Penninger JM Molecular control of bone remodeling and osteoporosis. 2000 Exp. Gerontol. pmid:11121682
Shalhoub V et al. Characterization of osteoclast precursors in human blood. 2000 Br. J. Haematol. pmid:11122091
Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. 2000 J. Bone Miner. Res. pmid:11127193
Sakuma Y et al. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. 2000 Infect. Immun. pmid:11083800
Riggs BL The mechanisms of estrogen regulation of bone resorption. 2000 J. Clin. Invest. pmid:11086020
Udagawa N et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. 2000 Endocrinology pmid:10965921
Yasuda H [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. 2000 Seikagaku pmid:10967683
Teitelbaum SL Bone resorption by osteoclasts. 2000 Science pmid:10968780
Lacey DL et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. 2000 Am. J. Pathol. pmid:10934148
Quinn JM et al. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. 2000 J. Bone Miner. Res. pmid:10934644
Min H et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. 2000 J. Exp. Med. pmid:10952716
Nakashima T et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. 2000 Biochem. Biophys. Res. Commun. pmid:10973797
Itoh K et al. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. 2000 J. Bone Miner. Res. pmid:10976996
Schinke T and Karsenty G Vascular calcification--a passive process in need of inhibitors. 2000 Nephrol. Dial. Transplant. pmid:10978374
Lorenzo J Interactions between immune and bone cells: new insights with many remaining questions. 2000 J. Clin. Invest. pmid:10995785
Teng YT et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. 2000 J. Clin. Invest. pmid:10995794
Børset M et al. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. 2000 Blood pmid:11001907
Hofbauer LC and Heufelder AE Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. 2000 J. Clin. Endocrinol. Metab. pmid:10902778
Rani CS and MacDougall M Dental cells express factors that regulate bone resorption. 2000 Mol. Cell Biol. Res. Commun. pmid:10860862
Tsurukai T et al. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. 2000 J. Bone Miner. Metab. pmid:10874596
Günther T and Schinke T Mouse genetics have uncovered new paradigms in bone biology. 2000 Trends Endocrinol. Metab. pmid:10856921
Huang L et al. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. 2000 Am. J. Pathol. pmid:10702390
Capparelli C et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. 2000 Cancer Res. pmid:10706080
Makhluf HA et al. Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. 2000 Biochem. Biophys. Res. Commun. pmid:10679262
Merewether LA et al. Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. 2000 Arch. Biochem. Biophys. pmid:10683254
Ross FP RANKing the importance of measles virus in Paget's disease. 2000 J. Clin. Invest. pmid:10712423
Tricot G New insights into role of microenvironment in multiple myeloma. 2000 Lancet pmid:10675068
Takayanagi H et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. 2000 Arthritis Rheum. pmid:10693864
Itonaga I et al. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. 2000 Ann. Rheum. Dis. pmid:10627423
Chikatsu N et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. 2000 Biochem. Biophys. Res. Commun. pmid:10631114
Gori F et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. 2000 Endocrinology pmid:11108292
Clohisy DR et al. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. 2000 J. Orthop. Res. pmid:11192258
Aubin JE and Bonnelye E Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. 2000 Osteoporos Int pmid:11193242
Wise GE et al. Osteoprotegerin and osteoclast differentiation factor in tooth eruption. 2000 J. Dent. Res. pmid:11201042
Kotake S et al. [Molecular mechanism of bone metabolism]. 2000 Nippon Naika Gakkai Zasshi pmid:11215116
Kanematsu M et al. [Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. 2000 Biol. Sci. Space pmid:12561872
Haynes DR et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. 2001 Rheumatology (Oxford) pmid:11426018
Szulc P et al. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. 2001 J. Clin. Endocrinol. Metab. pmid:11443182
Sakiyama H et al. Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. 2001 J. Bone Miner. Metab. pmid:11448014
Choi Y et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. 2001 Eur. J. Immunol. pmid:11449372
Kanzaki H et al. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. 2001 J. Dent. Res. pmid:11379890
Hein GE [Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. 2001 Z Rheumatol pmid:11383046
Morony S et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. 2001 Cancer Res. pmid:11389072
Kim KJ et al. Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. 2001 J. Biomed. Mater. Res. pmid:11410897
Abu-Amer Y IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. 2001 J. Clin. Invest. pmid:11390419
Kon T et al. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. 2001 J. Bone Miner. Res. pmid:11393777
Fazzalari NL et al. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. 2001 J. Bone Miner. Res. pmid:11393778
Bekker PJ et al. The effect of a single dose of osteoprotegerin in postmenopausal women. 2001 J. Bone Miner. Res. pmid:11204435
Stejskal D et al. Osteoprotegerin, RANK, RANKL. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426773
Stejskal D et al. Osteoprotegerin and bone density. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426776
Takemura M et al. Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. 2001 Metab. Clin. Exp. pmid:11172466
Gravallese EM et al. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. 2001 Arthritis Res. pmid:11178122
Makiishi-Shimobayashi C et al. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. 2001 Biochem. Biophys. Res. Commun. pmid:11181055
Price PA et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. 2001 Arterioscler. Thromb. Vasc. Biol. pmid:11597934
Nemec K and Schubert-Zsilavecz M [Future therapies for metabolic bone diseases. New concepts and targets]. 2001 Pharm Unserer Zeit pmid:11715689
Kuntz KA et al. An immunohistochemical study of osteoprotegerin in the human dental pulp. 2001 J Endod pmid:11716077
Hofbauer LC and Schoppet M Serum measurement of osteoprotegerin--clinical relevance and potential applications. 2001 Eur. J. Endocrinol. pmid:11720890
Ueland T et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. 2001 Eur. J. Endocrinol. pmid:11720891
Chikazu D et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. 2001 J. Bone Miner. Res. pmid:11697804
Khosla S Minireview: the OPG/RANKL/RANK system. 2001 Endocrinology pmid:11713196
Seidel C et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. 2001 Blood pmid:11568016
Fukagawa M et al. Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. 2001 Am. J. Kidney Dis. pmid:11576943
Sato T et al. Osteoprotegerin levels before and after renal transplantation. 2001 Am. J. Kidney Dis. pmid:11576949
Haynes DR et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. 2001 J Bone Joint Surg Br pmid:11521937
Hofbauer LC and Schoppet M Osteoprotegerin: a link between osteoporosis and arterial calcification? 2001 Lancet pmid:11498208
Sakai A et al. 1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. 2001 J. Bone Miner. Metab. pmid:11498729
Ikeda T et al. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. 2001 J. Bone Miner. Res. pmid:11499864
Thomas GP et al. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. 2001 J. Endocrinol. pmid:11479141
Allan GF et al. Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. 2001 Steroids pmid:11546554
Feige U Osteoprotegerin. 2001 Ann. Rheum. Dis. pmid:11890662
Giuliani N et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. 2001 Blood pmid:11739153
Croucher PI et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. 2001 Blood pmid:11739154
Dhore CR et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. 2001 Arterioscler. Thromb. Vasc. Biol. pmid:11742876
Ramalho AC et al. Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. 2001 Cytokine pmid:11792122
Yano K et al. Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. 2001 J. Bone Miner. Metab. pmid:11685652
Kawahara N et al. Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. 2001 Chem. Pharm. Bull. pmid:11605678
Boissy P et al. RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. 2001 Biochem. Biophys. Res. Commun. pmid:11606048

Table of Content